CARDIOVASCULAR DISEASES

Cardiovascular Biochemistry

Main lines of research

Atherosclerosis mechanisms

  • Analysis of apolipoprotein J (apoJ) as a marker of CVR.
  • Use of mimetic peptides derived from apoJ as therapeutic tools.
  • Involvement of LDL(-) on lipid accumulation in cardiomyocytes and heart failure.

Inflammatory mechanisms induced by LDL(-) on monocytes from patients with diabetes.

  • Diagnosis of chronic or acute cardiovascular diseases.
  • Development of algorithms for ruling-out acute coronary disease.
  • Assessment of new biomarkers of acute cardiovascular disease: cardiac troponins, natriuretic peptides, ST-2.
  • Development of methods for point-ofcare biomarker measurement.
  • Vulnerability markers in atheromatous plaque: electronegative LDL, LDL size, HDL function, myeloperoxidase, phospholipase.

Challenges

  • Determine the intracellular mechanisms involved in the inflammatory response induced by LDL(-) and the components of the particle that entail atherogenicity.
  • Analyse the therapeutic potential of mimetic peptides derived from apo J to delay the development of atherosclerosis in animal models.
  • Demonstrate that electronegative LDL is a marker of vulnerable atheromatous plaque.
  • Find new markers of cardiovascular risk in diseases such as diabetes, HIV or cardiac failure.

This website uses cookies to improve the browsing experience and perform analytical tasks. If you continue browsing, we understand that you agree our cookies policy. More information